Figure 2.

PPARγ activation inhibits cell growth in prostate cancer cell lines. (A) Time course and dose-response inhibition of cell growth of DU145 treated with troglitazone. (B) Comparison of the growth inhibitory effects of troglitazone at 10 μM in LNCaP, DU145, and PC3 cells. (C) Growth inhibition in DU145 cells treated for 7 days with 5 μM rosiglitazone (BRL) and 5 μM 15-deoxy-Δ^12,14PGJ₂ (PGJ2). DU145 treated with 10 μM M2, an inactive metabolite of troglitazone, 10 μM of Wy, or 5 μM of GW 00233, PPARα and PPARδ ligands, respectively, did not show any growth inhibition compared with troglitazone-treated cells.